OTCMKTS:ASPCF

Acerus Pharmaceuticals (ASPCF) Stock Price, News & Analysis

Acerus Pharmaceuticals logo
$0.22 0.00 (0.00%)
As of 07/21/2023

About Acerus Pharmaceuticals Stock (OTCMKTS:ASPCF)

Key Stats

Today's Range
$0.22
▼
$0.22
50-Day Range
$0.22
▼
$0.22
52-Week Range
$0.22
▼
$8.16
Volume
N/A
Average Volume
1,500 shs
Market Capitalization
$1.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Acerus Pharmaceuticals was a Canadian specialty pharmaceutical company focused on developing and commercializing products in men’s health. Its portfolio included Natesto, a nasal testosterone gel for treating men with certain forms of testosterone deficiency, and Spedra, a brand of avanafil used to treat erectile dysfunction in Canada.

Formerly known as Trimel Pharmaceuticals, Acerus operated in Canada and the United States through product commercialization and licensing arrangements. Its business and product portfolio changed over time, and the company later entered insolvency proceedings.

AI Generated. May Contain Errors.

Receive ASPCF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acerus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ASPCF Stock News Headlines

Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
Acerus Reports Third Quarter 2022 Financial Results
Acerus Announces Initiation of Strategic Review
See More Headlines

ASPCF Stock Analysis - Frequently Asked Questions

Acerus Pharmaceuticals' stock was trading at $0.22 at the beginning of the year. Since then, ASPCF stock has increased by 0.0% and is now trading at $0.22.

Acerus Pharmaceuticals shares reverse split on the morning of Friday, April 29th 2022.The 1-200 reverse split was announced on Friday, April 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Company Calendar

Today
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
OTCMKTS:ASPCF
CIK
N/A
Employees
14
Year Founded
2008

Profitability

EPS (Trailing Twelve Months)
($3.57)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$33.82 million
Net Margins
-924.33%
Pretax Margin
-924.33%
Return on Equity
N/A
Return on Assets
-74.62%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.67
Quick Ratio
0.34

Sales & Book Value

Annual Sales
$2.12 million
Price / Sales
0.80
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($3.38) per share
Price / Book
-0.07

Miscellaneous

Outstanding Shares
7,708,000
Free Float
N/A
Market Cap
$1.70 million
Optionable
Not Optionable
Beta
0.69

Social Links

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

This page (OTCMKTS:ASPCF) was last updated on 7/21/2023 by MarketBeat.com Staff.
From Our Partners